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Background. Lower esophageal sphincter (LES) electrical stimulation therapy (EST) has been shown to
improve outcome in gastroesophageal reflux disease (GERD) patients at 1 year. The aim of this open-
label extension trial (NCT01578642) was to study the 2-year safety and efficacy of LES-EST in GERD
patients.
Methods. GERD patients responsive partially to proton pump inhibitors (PPI) with off-PPI GERD
health-related quality of life (HRQL) of $20, 24-hour esophageal pH #4.0 for >5% of the time, hiatal
hernia #3 cm, and esophagitis LA grade C or lower participated in this trial. Bipolar stitch electrodes
and a pulse generator (EndoStim BV, The Hague, The Netherlands) were implanted laparoscopically.
LES-EST at 20 Hz, 215 ms, 3-8 mAmp was delivered over 30-minute sessions, 6-12 sessions per day,
starting on day 1 after implantation. Patients were evaluated using GERD-HRQL, symptom diaries,
Short Form-12, and esophageal pH testing at regular intervals. Stimulation sessions were optimized
based on residual symptoms and esophageal pH at follow-up.
Results. Twenty-five patients (mean age [SD] = 52 [12] years; 14 men) were implanted successfully; 23
patients participated in the 2-year extension trial, and 21 completed their 2-year evaluation. At 2 years,
there was improvement in their median GERD-HRQL on LES-EST compared with both their on-PPI (9
vs 0; P = .001) and off-PPI (23.5 vs 0; P < .001) baseline scores. Median 24-hour distal esophageal
acid exposure improved from 10% at baseline to 4% (per-protocol analysis; P < .001) at 2 years with
71% demonstrating either normalization or a $50% decrease in their distal esophageal acid exposure.
All except 5 patients (16/21) reported complete cessation of PPI use; only 2 patients were using a PPI
regularly ($50% of days). There was significant improvement in sleep quality and daily symptoms of
heartburn and regurgitation on LES-EST. At baseline, 92% of the subjects (22/24) reported that they
were ‘‘unsatisfied’’ with their condition off-PPI and 71% (17/24) on-PPI compared with 0% (0/21)
‘‘unsatisfied’’ at the 24-month visits on LES-EST. There were no device- or therapy-related serious
adverse events and no untoward sensation or dysphagia reported with LES-EST.
Conclusion. LES-EST is safe and effective for treating patients with GERD over a period of 2 years. LES-
EST resulted in a significant and sustained improvement in GERD symptoms, and esophageal acid
exposure and eliminated PPI use in majority of patients (16 of 21). Further, LES-EST was not associated
with any gastrointestinal side effects or adverse events. (Surgery 2015;157:556-67.)From the Department of Surgery,a CCO Obesidad y Diabetes; the Department of Gastroenterology,b Clinic
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Rodrıguez et al 557GASTROESOPHAGEAL REFLUX DISEASE (GERD) is a global
public health problem. The definition of GERD by
theMontreal consensus emphasizes both subjective
complaints and complications of GERD, defining
GERD as ‘‘a condition that develops when the reflux
of stomach contents causes troublesome symptoms
and/or complications.’’1 GERD symptoms are com-
mon and affect 10–20% of adults in Western coun-
tries and #40% in the United States.2,3 Proton
pump inhibitors (PPI) are potent suppressors of
gastric acid secretion and have improved the treat-
ment of erosive GERD; however, a substantial num-
ber of patients remain symptomatic despite
maximal dose therapy. A meta-analysis of random-
ized, controlled trials indicate a high prevalence of
incomplete response or nonresponse of reflux
symptoms to PPI therapy.4,5 A number of mecha-
nisms are thought to contribute to incomplete
response, an important one being the continuous
reflux of weakly acidic or nonacidic gastric contents
while on PPIs, because PPIs target acid secretion,
rather than the lower esophageal sphincter (LES)
dysfunction permitting persistent and unrestrained
reflux of gastric contents into the esophagus.6
Inadequate symptom control has been cited as
one of the main reasons that drive patients and
physicians to seek surgical therapies for GERD.7
The cost of life-long pharmacologic therapy and
potential risks of long-term acid suppression are
also of concern to patients and physicians.8 Surgi-
cal fundoplication is effective, but is associated
with long-term failures and adverse effects7,9 This
unmet need has led to multiple attempts at devel-
oping less-invasive endoscopic and surgical thera-
pies for the treatment of GERD.10,11
‘‘A desirable surgical/endoscopic GERD treat-
ment should render an effect that is effective, yet
less disruptive, has fewer adverse effects than that of
a fundoplication, and be truly reversible.’’12 Electri-
cal stimulation therapy (EST) has been used success-
fully in treating some gastrointestinal motility
disorders, such as gastroparesis and fecal inconti-
nence, and has the required characteristics for being
that ‘‘desirable’’ surgical therapy for GERD sufferers
that are not satisfied with their medical therapy and
are not interested in traditional antireflux surgery.
The EndoStim LES stimulation system (EndoStim
BV, The Hague, The Netherlands) is an implantable
neurostimulator developed for the treatment of
GERD. We demonstrated previously that temporary
LES stimulation resulted in sustained improvement
in LES pressure in GERD patients without any effect
on LES relaxation.13 We reported subsequently the
safety and efficacy of LES-EST using a permanent
LES stimulator implant in GERD patients at their1-year follow-up.14 This is the 2-year report of that
cohort of subjects treated with LES-EST.
METHODS
Study objectives. The objectives of this prospec-
tive, open-label, single-center, treatment-only trial
were to assess the safety of chronic intermittent
LES-EST and to evaluate the effect of stimulation
on GERD symptoms, medication use, esophageal
acid exposure, and esophageal motor function in
subjects with GERD. The study was registered
(NCT01578642) and approved by the local Ethics
Committee Servicio de Salud Metropolitano Oriente
Comite Etica Cientifico, Santiago, Chile. All subjects
signed an informed consent form before partici-
pating in the study.
Subject population. Key inclusion criteria
included subjects 21–65 years of age with a history
of heartburn, regurgitation, or both for$6 months
prompting physician recommending continual
daily use of PPI before study entry. All had a baseline
GERDhealth-related quality of life (HRQL) score of
$20 off PPI and a symptomatic response to a course
of GERD therapy ($2 weeks) with a GERD-HRQL
score improvement (see below) of $10 on PPI.
Included subjects exhibited excessive distal esoph-
ageal acid exposure during 24-hour pH measure-
ment defined as a pHof#4 for>5%of total or>3%
of supine, time off, antisecretory therapy. Subjects
had a resting LES end-expiratory pressure of
$5 mmHg on high-resolution manometry. Subjects
had esophageal body contraction amplitude of
$30 mmHg for $70% of swallows and $50%
peristaltic contractions on high resolution manom-
etry. Subjects with esophagitis grade C or lower (LA
classification) on upper endoscopy performed
within 6 months of enrollment were included.
Subjects with Barrett’s epithelium (maximal extent
(M2) > 2 cm; circumferential extent (C1) > 1 cm),
any grade of dysplasia, or a hiatal hernia$3 cmwere
excluded. Subjects with a body mass index of
>35 kg/m2, uncontrolled type 2 diabetes mellitus
(defined as a hemoglobin A1c of >9.5 in the previ-
ous 6 months), a history of type 2 diabetes mellitus
for >10 years, or those with type 1 diabetes mellitus
were excluded also. Detailed inclusion criteria,
exclusion criteria, and study details have been re-
ported previously.14
LES stimulation system: Investigational device
description. The LES stimulation system is made
up of 3 components: a bipolar electrical stimula-
tion lead, an implantable pulse generator (IPG),
and an external programmer (Fig 1, A).
Stimulation lead. A sterile, bipolar stitch elec-
trode stimulation lead is used in conjunction with
Fig 1. (A) EndoStim wireless programmer, implantable pulse generator and bipolar stimulation lead. Inset shows the 2
stimulation electrodes and the butterfly used for anchoring the electrode at the lower esophageal sphincter. (B) Endo-
Stim System Implant in a patient. Electrode position and implantable pulse generator (IPG) implant location. Bipolar
stitch electrodes are placed in the abdominal esophagus anteriorly in an inline configuration 1 cm apart. The lead is
connected to the IPG that is implanted in the subcutaneous pocket in the anterior abdomen.
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of 2 platinum–iridium electrodes. The stimulation
lead is 45 cm long with the 2 electrodes measuring
0.5 mm in diameter and 10 mm in length each.
The 2 electrodes are implanted in the muscularis
propria of the LES.
IPG. The IPG device has a casing made of
titanium while containing a medical-grade lithium
battery, microelectronics, communication coils,
and an inclinometer for sensing the subject’s
posture. It is sealed hermetically to prevent dam-
age to the device from biologic fluids. The IPG also
has stainless steel contacts encapsulated in an
implantable medical-grade epoxy for connection
with the stimulation lead.
External programmer. The external program-
mer is used to interrogate and program the IPG.
The programmer has 3 components: a commer-
cially available laptop personal computer, an inter-
face box that contains electronics, and a wand that
contains communications electronics.
The LES stimulation system delivers therapy
at 215-ms pulse-width at 20 Hz delivered in
30-minute sessions that can be adjusted non-
invasively and customized to individual patient
needs. Electrical stimulation can be optimized as
follows: the stimulation parameters can be
adjusted using the external programmer; addi-
tional stimulation sessions can be added or the
timing of existing sessions changed; and stimu-
lation amplitude and electrode polarity can be
adjusted at follow-up to address suboptimal symp-
tom or pH response. The device includes a
sensor to detect upright and supine positions,
and the stimulation algorithm can be customized
based on patient position to address supine/
nocturnal reflux.LES stimulator implant procedure. After base-
line evaluations, eligible subjects underwent a
laparoscopic procedure to implant the EndoStim
LES Stimulation System. A schematic of the
EndoStim system implant is shown in Fig 1, B
and details of the operative procedure were
reported previously.15 In brief, 4–5 trocars were
typically used, with $1 being a 10-mm port for
introduction of the lead into the abdominal cavity;
the rest were 3- or 5-mm ports. For the lead
implant, the anterior right aspect of the abdominal
esophagus was exposed through dissection of the
paraesophageal fat and pars flaccida of the hepato-
gastric ligament. A rectangular longitudinal area of
approximately 3 3 1 cm is needed in which the
electrodes are implanted. This approach mini-
mized dissection of the phreno-esophageal attach-
ment and damage to the anterior vagal nerve. The
2 stitch electrodes were implanted via a superficial
bite into the LES muscle along the main esopha-
geal axis with approximately 10 mm between the
electrodes. Each electrode was then secured by a
clip on the proximal edge of the electrode on to
the nylon suture wire and also by suturing the
distal anchoring ‘‘butterfly’’ present on the back
end of the electrode. Upper gastrointestinal endos-
copy was performed to verify electrode position in
the LES and to confirm that no perforation of the
esophageal lumen had occurred with the needle or
electrode. No hiatal intervention was performed in
any patient in this trial. The abdomen was desuf-
flated, the skin incision for the pulse generator
performed, and a subcutaneous pocket created
by blunt dissection. After the connector was
attached to the pulse generator, a functionality
test was performed using the external program-
mer. The pulse generator was placed into its
Surgery
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into the abdominal cavity and placed along the
left abdominal wall away from the midline. After
recovery and observation of $12 hours (for
recording of any symptoms secondary to the device
placement), the device was interrogated and
lead impedance checked to ensure proper
functionality.
Cardiac activity was monitored via electrocardi-
ography while the stimulation was delivered for the
first time and during the subsequent 2-hour
observation period. Once the stimulation parame-
ters of the device were programmed, subjects were
discharged. The subjects were taken off acid-
suppressive therapy at discharge and instructed
to take per-protocol, as-needed antacid therapy. All
patients were advised to follow standard GERD diet
and lifestyle instructions.
Symptom assessment and esophageal tests.
Symptoms of GERD were assessed using the
GERD-HRQL, a validated questionnaire.16 The
questionnaire provides a composite score as well
as an assessment of individual symptoms. Quality
of life was also assessed by the Short Form
(SF)-12 Health Survey---Physical and Mental
Component Scores.27 Symptom assessment was
carried out at baseline while the patient was on
PPI therapy and after 2 weeks off PPI therapy.
The variables were evaluated again at follow-up
while on LES-EST.
Esophageal acid exposure was assessed using
24-hour esophageal pH-metry (AL-1 system for pH
monitoring, Ver. 1.26; Alacer Biomedica, S~ao
Paolo, Brazil) and sensors positioned in the
esophageal body 5 and 23 cm proximal to the
manometric upper border of the LES with the
patient off PPI therapy for at least 5 days. Of the 23
subjects, 22 underwent esophageal pH testing at
the 12-month follow-up visit. One subject refused
the 12-month pH test. Of the 21 subjects who
completed the 24-month visit, 18 underwent
esophageal pH testing. Three subjects refused
the 24-month pH test.
Substudy to evaluate the effect of blinded turn-
off of LES-EST. As part of a substudy approved by
our ethics committee, 3 patients with no GERD
symptoms or medication use and normal esopha-
geal acid exposure at the 12-month time point
underwent blinded turn-off of LES-EST after their
18-month follow-up. Additionally, 1 patient also
with no GERD symptoms or medication use and
normal 12-month esophageal pH had her therapy
turned off accidentally at month 15 by inadvertent
use of magnet therapy for her arthritis. These
patients had their esophageal pH testingperformed after cessation of LES-EST for
$3 months to evaluate the effect of cessation of
LES-EST on esophageal acid exposure.
Concomitant medications/treatments. Subjects
were allowed to take antacid medications as
needed per-protocol for residual GERD symptoms
during the study. Those with persistent symptoms
on LES-EST despite antacids were allowed PPI
medications. All medication use was recorded in
the daily symptoms and antacid use diary
completed by the subjects.
Statistical analysis. Statistical analysis was per-
formed by an independent statistician (JB). A
sample size of 22 patients provided 90% power
(2-sided alpha of 0.05) to detect a mean (SD)
difference of 7 (10) on the composite GERD-
HRQL score from baseline to 24 months. Allowing
for 10% patient dropout, a sample size of 25
patients was chosen as the final enrollment target.
Safety evaluation was descriptive in nature and
included the incidence, severity, and type of adverse
effects, as well as clinically important changes or
abnormalities in the physical examination, vital
signs, clinical tests, and electrocardiogram.
The effect of LES stimulation on patient symp-
toms was measured using the GERD-HRQL. Qual-
ity of life was measured using the SF-12 Physical
and Mental Component Scores (both on PPI
therapy and after 2 weeks off PPI therapy).
Symptoms and medication use were recorded on
a daily patient symptom diary for a 2-week period
before the assessment. All comparisons were made
at the P < .05 level using paired Wilcoxon tests.
Statistical and descriptive comparisons of study
results were made utilizing SAS version 9.3 (Chi-
cago, IL) and R version 2.11.1 (available from
http://www.r-project.org/).
RESULTS
Patient characteristics. Seventy-five subjects
were consented and enrolled in the study.
Twenty-six subjects were found to be eligible and
underwent a laparoscopic procedure. One subject
was excluded, because a large (5-cm) hiatal hernia
was identified at laparoscopy, and device implan-
tation was not performed. Twenty-five subjects
underwent implantation of the LES stimulation
system. Approximately 4 weeks after the device
implant, 1 subject requested and underwent
removal of the IPG under local anesthesia and
subsequently withdrew voluntarily from the study.
Detailed subject accountability is provided in Fig 2.
The mean age (SD) of subjects implanted in the
trial was 52 (12) years, and mean body mass index
(SD) was 28 (3.2) kg/m2. Based on body mass
Fig 2. Subject accountability.
Table I. Baseline patient characteristics and
relevant medical history
Characteristics Value
Age, mean (SD), y 52.0 (12)
BMI, mean (SD) 27.7 (3.2)
Normal (<25), n 5
Overweight ($25–<30), n 13
Obese ($30), n 7
Sex, n
Male 14
Female 11
Patients using daily PPI, n/N (%) 24/24 (100)
Duration of GERD symptoms (y),
mean (SD)
11.0 (7.9)
Median (IQR) 10.0 (7–11)
Duration of PPI use (y), mean (SD) 5.6 (3.4)
Median (IQR) 5.0 (3–10)
GERD-HRQL score
Total score on PPI therapy,
mean (SD)
9.8 (6.2)
Median (IQR) 9.0 (6–10)
Not satisfied, n/N (%) 17/24 (71)
Total score off PPI therapy,
mean (SD)
23.7 (3.5)
Median (IQR) 23.5 (21–25.3)
Not satisfied, n/N (%) 22/24 (92)
Heartburn, frequency/week off
PPI (%), mean (SD)
86 (15)
Median (IQR) 92 (85, 93)
Regurgitation, frequency/week off
PPI (%), mean (SD)
57 (37)
Median (IQR) 65.5 (16.2–92.3)
Nocturnal heartburn, frequency/
week off PPI (%), mean (SD)
59 (35)
Median (IQR) 71 (36–85)
Nocturnal regurgitation, frequency/
week (off PPI; %), mean (SD)
39 (38)
Median (IQR) 31 (0–74.5)
Total proportion of 24-hour period
with pH < 4 (%), mean (SD)
11.4 (5.8)
Median (IQR) 10.1 (7.8–13.0)
Hiatal hernia, n/N (%)
None 22/25 (88)
<2 cm 2/25 (8)
>2 cm 1/25 (4)
BMI, Body mass index; GERD, gastroesophageal reflux disease; HRQL,
health-related quality of life; IQR, interquartile range; PPI, proton
pump inhibitor; SD, standard deviation.
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normal (<25 kg/m2) and 80% of subjects were
classified as being overweight or obese ($25 kg/
m2). All patients were on chronic, daily PPI ther-
apy and 6 (24%) were on twice daily PPI. The
median duration of GERD diagnosis was 10.6 years
with median duration of PPI use of 5.5 years before
enrollment. Dissatisfaction with their control of
GERD before implantation while on PPI therapy
was reported by 71% of patients (17/24), and
79% (19/24) reported bothersome GERD symp-
toms on $1 of the GERD-HRQL question
(score $ 2) while on PPI. The most important
impact of GERD on quality of life while taking
PPIs were persistent heartburn (46%; 11/24),
effect of heartburn on diet (33%; 8/24), effect of
medication on daily life (25%; 6/24), and waking
up owing to heartburn (33%; 8/24). Baseline
patient and disease characteristics for the 24
patients are shown in Table I.
LES-EST treatment parameters. EST was initi-
ated within 24 hours of the implant procedure
with 215 ms pulse at 20 Hz delivered for 30 minutes
at median of 4 sessions per day (interquartile
range [IQR], 3–5) and at median amplitude of
3.5 mA (IQR, 3.2–4.1). The details of parameter
changes between baseline and 12 months have
been reported previously.14 The median number
of sessions at month 12 were 12 sessions per day
(IQR, 8–12). The median stimulation current at
month 12 was 5.1 mA (IQR, 4.1–5.8). The median
increase in the stimulation current from baseline
to month 12 was 1.8 mA (IQR, 1.2–2.2). Allpatients were programmed with a fixed stimulation
protocol of 215 ms pulse width, 5 mA amplitude,
30-minute sessions delivered 12 times per day at
or after their 12-month visit. These parameters
were continued for the remainder of their follow-
up, except for 3 patients who underwent the
blinded turn off after their 18-month follow-up
visit.
Surgery
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subjects were reported. Two serious adverse events
were reported in 2 subjects (2/25 [8%]), and both
were adjudicated as not related to the procedure,
device, or therapy by an independent data safety
monitoring board. One subject reported an
episode of acute, retrosternal chest pain occurring
2 months after the implant procedure and under-
went a negative cardiac evaluation and was diag-
nosed with noncardiac chest pain. The subject
reported experiencing similar events before enroll-
ment in the study and continued with LES-EST
without recurrence of chest pain. The other sub-
ject was hospitalized for an elective thyroidectomy
3 months after the implant.
Of the remaining 63 nonserious adverse events,
12 were adjudicated to be possibly or probably
related to the device or procedure. Six events in 6
subjects were related to the procedure; nausea or
vomiting was noted in 3 subjects occurring on or
the day after the procedure and resolving in
#1 day; pain or discomfort in the shoulder and a
‘‘hypertensive episode’’ occurring the day after the
procedure and lasting for 1 day were reported in 2
patients. A superficial skin infection at the pocket
site was reported in 1 patient. Six events in 5
subjects were reported as pain or discomfort in the
abdomen possibly or probably related to the
device. One subject had 2 events, 1 reported as a
‘‘psychotic disturbance,’’ and a second event re-
ported as a ‘‘nervous breakdown’’ adjudicated as
possibly related to the device and/or procedure.
Fifty-one adverse events were adjudicated as not
related to device or procedure. Among unrelated
adverse events, events involving the respiratory
system were the most common with 19 in 13
subjects reported. Of these, the event type ‘‘cold’’
was reported in 17 of the 19 patients.
No patient reported gastrointestinal side effects
of new-onset dysphagia, bloating, inability to belch,
or diarrhea associated with LES stimulation.
GERD-HRQL and daily symptom diaries. GERD
symptoms improved immediately on initiating LES
stimulation and cessation of daily PPI in most
patients, and the remaining patient symptoms
improved over the next 3 months with optimiza-
tion of LES stimulation. A significant (>50%)
improvement in GERD-HRQL scores compared
with baseline off-PPI scores was reported in 18 of
24 patients (75%; median GERD-HRQL, 4; IQR,
1.3–9.5) at 1 month and 24 of 24 patients (100%;
median GERD-HRQL, 2; IQR, 0–4) at the 3-month
follow-up.
Baseline median composite GERD-HRQL
scores were 9 on-PPIs and 23.5 off-PPIs. At the6-, 12, 18-, and 24-month visits, median GERD-
HRQL scores were 2, 2, 0, and 0, respectively
(P < 0; Table II). Improvement in median GERD-
HRQL at 6, 12, 18, and 24 months were statisti-
cally better (P # .002) than both median baseline
on-PPI and off-PPI scores.
At baseline, 92% of subjects (22/24) reported
that they were ‘‘unsatisfied’’ with their condition
off PPI and 71% (17/24) on PPI compared with
0% (0/21) ‘‘unsatisfied’’ at the 24-month visits on
LES-EST. The subjects’ satisfaction with their con-
dition was better than both on-PPI and off-PPI
baseline satisfaction (P < .001).
At baseline, 38% of subjects (9/24) on PPI and
71% of subjects (17/24) off PPI reported symp-
toms (individual GERD-HRQL scores $ 1) of
difficulty swallowing, respectively, versus 5% of
subjects (1/21) at the 24-month follow-up visit
(Fig 3). A total of 21% (5/24) and 83% (20/24) of
subjects reported odynophagia at baseline on PPI
and off PPI, respectively, versus 10% (2/21) of sub-
jects at the 24-month follow-up visit (Fig 3). There
were no new-onset dysphagia or odynophagia
reported with LES-EST during the 2 years of
follow-up.
Sleep quality, assessed by questionnaire evalu-
ating the effect of heartburn on sleep, improved
from a baseline median of 1 on PPI and 2.5 off PPI
to a median of 0 at their 6-, 12-, and 24-month
follow-up visits. Seventy-one percent (17/24) and
96% (23/24) of subjects reported symptoms
affecting sleep at baseline on PPI and off PPI,
respectively, versus 10% (2/21) of subjects at the
24-month follow-up visit (Fig 3).
Subject daily diary symptoms. Symptoms of
heartburn and regurgitation were evaluated using
a 14-day symptom diary. Eighteen subjects were
available for pairwise analysis of diary data at their
2 year follow-up. At the baseline visit, subjects
reported a median 92% of days with heartburn off
PPIs, which decreased declined to 14% at
6 months, 13% at 12 months, and 7% at both 18
and 24 months (P < .001; Fig 4). Similarly, subjects
reported 71% of nights with heartburn at baseline
off PPIs, which decreased to a median of 0% at the
6-, 12-, and 24-month follow-up visits (P < .001 for
all times; Fig 4).
At the baseline visit, subjects reported a median
66% of days with regurgitation off PPIs. This
decreased to a median of 0% at the 6-, 12-, and
24-month visits (P < .001). Similarly, subjects
reported a median 31% of nights with regurgita-
tion at baseline off PPIs, which declined to a me-
dian of 0% at the 6-, 12-, and 24-month follow-up
visits (P < .01 at all time points vs baseline off PPI).
Table II. Baseline and 24-month post-therapy results
Characteristic
Baseline 24 Months
P valueMedian IQR n Median IQR n
GERD–HRQL
On PPI 9 6–10 24 0 0–3 21 .002
Off PPI 23.5 21–25.3 24 — — <.0001
SF-12 mental health
On PPI 43 40.5–53 22 56 44–62 21 .058
Off PPI 49 39.2–54.2 24 — — — .082
SF-12 physical health
On PPI 47 42.5–51.5 22 55 53–57 21 .0007
Off PPI 46.5 41.2–49 24 — — — .0001
% 24-hour distal esophageal pH < 4.0 (intent-to-treat analysis)*
Total 10.1 7.8–13.0 24 4.8 3.4–7.0 18 .001
Upright 10.4 8.5–14.9 24 5.3 2.1–7.1 18
Supine 6 2–13.2 24 0.8 0.3–11 18 .66
DeMeester score 36.6 29.6–50.2 24 16.1 12.2–29.1 18 .002
Patients with abnormal distal esophageal pH*
(<4 for >4%), n/N (%)
23/24 (96%) — — 11/18 (61%) — — —
% 24-hour proximal esophageal pH < 4.0
Total 0.4 0.1–1.3 21 0 0–0.1 18 .001
Upright 0.6 0.2–1.9 21 0 0–0.1 18 <.001
Supine 0 0–0.1 21 0 0–0 18 .03
Patients with abnormal proximal esophageal
pH* (<4 for >1.1%), n/N (%)
7/21 (33%) — — 0/18 (0%) — — —
*Four patients with normal esophageal pH at their 12 months follow-up had LES stimulation turned off for at least 3 month prior to their 24 month
follow-up; all had abnormal esophageal pH at 24 month. Their results are included in this ITT analysis.
BMI, Body mass index; GERD, gastroesophageal reflux disease; HRQL, health-related quality of life; IQR, interquartile range; PPI, proton pump inhibitor.
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symptom severity as none, mild, moderate, or
severe for heartburn and regurgitation indepen-
dently. The medians across subjects of percentage
days with each severity category demonstrated a
clinically meaningful decrease in heartburn and
regurgitation symptom severity at all time points
on LES-EST (Fig 5). Subjects reported none or
mild heartburn symptoms for a median 17% of
diary days at baseline off PPI, which increased to
93% after 24 months of treatment. Subjects
reported none or mild regurgitation symptoms
for a median 18% of diary days at baseline off
PPI, which increased to 100% after 6 months of
treatment and stayed at 100% through 24 months
of treatment.
Global quality of life (SF-12): Mental compo-
nent score and physical component score. At the
baseline visit, the median SF-12 mental component
score was 43 on PPI and 49 off PPI. The median
SF-12 mental component score improved to 54 at
the 6-month visit over both baseline on- and off-
PPI scores (P = .002). Mental component scores
remained constant at the 12- and 24-month
follow-up visits (Table II).At the baseline visit, the median SF-12 physical
component score was 47 on PPI and 46.5 off
PPI. Median SF-12 physical component scores
improved to 54 at the 6-month visit and were
better than baseline off-PPI scores through the
24-month visit at which time the scores were 55
(P < .05 vs baseline; Table II).
Esophageal acid exposure. At the baseline visit
for 20 patients treated with per-protocol contin-
uous therapy through their 24-month follow-up,
median % 24-hour esophageal pH < 4.0 was 10.8%
(Fig 6). Median % 24-hour esophageal pH < 4.0
was 3.7% (n = 18; P < .001) at 12 months, and
4.1% at 24 months (P = .001; n = 14; per-protocol
continuous therapy), respectively. Seventy-one
percent of subjects demonstrated either normaliza-
tion (pH of <4 for <4% of 24-hour recording) or
$50% decrease in their distal esophageal acid
exposure. Fifty percent of subjects demonstrated
a normalized pH, and an additional 21% demon-
strated a pH that was improved by >50%, although
not normalized. At the baseline visit, median %
24-hour supine acid exposure was 6% and
decreased to 0.4% and 0.8% at the 12- and 24-
month visits, respectively (intent-to-treat analysis).
Fig 3. Percent subjects reporting gastroesophageal reflux disease (GERD) affecting their swallowing and sleep on
GERD health-related quality of life questionnaires. No new-onset difficulty swallowing or painful swallowing reported.
EST, Electrical stimulation therapy; PPI, proton pump inhibitor.
Fig 4. Subject daily diary symptoms frequency at base-
line off and on proton pump inhibitor (PPI) and on
lower esophageal sphincter electrical stimulation ther-
apy (EST) at 12 and 24 months. Results are shown as me-
dian values with interquartile range.
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their 24-month follow-up. Of these 3 subjects, 2
demonstrated improvement of $50% compared
with both on-PPI and off-PPI GERD-HRQL scores;
1 subject demonstrated suboptimal (<50%) symp-
tom improvement. One of these 3 subjects used
PPIs occasionally at their 2-year follow-up, whereas
the other 2 were using PPIs regularly ($50% of
diary days).
The median DeMeester score at baseline was
37.5 (n = 20) and improved to 17.7 (n = 18) and14.6 (n = 14) at the 12- and 24-month visits, respec-
tively, indicating a reduction in distal esophageal
acid exposure in patients treated with per-
protocol continuous therapy.
Effect of blinded turn off of LES-EST. Three
patients underwent blinded turn off LES-EST after
their 18-month follow-up and 1 patient had her
therapy accidentally turned off by inadvertent use
of magnet therapy for her arthritis at month 15. Of
these 4 patients, only 1 reported recurrence of
GERD symptoms at their 3-month visit after
blinded turn off. On esophageal pH testing, all 4
patients demonstrated worsening in their distal
esophageal acid exposure compared with their on-
therapy 12-month acid exposure that, even after
>3 months of cessation of LES-EST, still had not
returned to their baseline esophageal acid expo-
sure (Fig 6).
PPI medication use. At baseline, all subjects
were taking daily PPI medications and 6 subjects
(25%) were taking twice-daily PPI medications. PPI
use on <50% of the daily diary days was defined as
‘‘occasional use’’ and PPI use on $50% of the daily
diary days was defined as ‘‘regular use.’’ Twenty-one
subjects completed daily diary entries at the 12-
and 24-month visits. At the 12-month visit, 20 of 21
subjects (95%) were not taking any PPI, 1 of 21
subjects (5%) reported occasional PPI use, and no
subjects reported regular PPI use. At the 24-month
visit, 16 of 21 subjects (76%) were not taking any
PPI, 3 of 21 subjects (14%) reported occasional
use, and 10% reported regular use of PPI. Median
Fig 5. Subject daily diary. (A) Heartburn symptoms severity (median, interquartile rage [IQR]; % diary days) and (B)
regurgitation symptoms severity (median, interquartile rage [IQR]; % diary days). EST, Electrical stimulation therapy.
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#0.1 pills per day at 3, 6, 12, and 24 months follow-
up (P < .001 by Wilcoxon paired test at each time
point).
DISCUSSION
This is the first report of 2-year results of LES-
EST showing a sustained improvement in GERD
outcomes. Patients reported sustained improve-
ment in GERD-HRQL and symptoms assessed by
daily symptom diary, elimination of need of daily
GERD medications, and improvement in their
esophageal acid exposure. Our preliminary expe-
rience with temporary turn off of LES stimulation
for $3 months suggests that the improvement in
esophageal acid exposure was a result of LES-EST.
Additionally, chronic LES stimulation may result in
improvement in GERD that is sustained after the
cessation of EST.There is an increasing realization of incom-
plete response to PPI therapy among GERD
patients. A meta-analysis of randomized,
controlled studies in the management of GERD
conducted in secondary care practices reported a
partial or nonresponse of their reflux symptoms to
PPI therapy in 19–44% of GERD patients.4 Com-
parable rates were reported recently in a system-
atic review of persistent reflux symptoms in
patients on PPIs evaluated in primary care and
community studies.5 In this review, the persistence
of GERD symptoms was associated with decreased
psychological and physical well-being. A recent
observational study conducted in primary care as
well as specialized settings supported these find-
ings by reporting high prevalence of incomplete
response to PPI therapy that was associated with
considerable direct and indirect costs and a sub-
stantial impairment in quality of life and work
Fig 6. Change in median (interquartile range [IQR] %) 24-hour distal esophageal pH (% 24-hour pH < 4.0; median
[IQR]). Four patients had therapy interrupted for $3 months before the 24-month follow-up. *P < .001 versus baseline
at months 12 and 24. There was no difference between 12 and 24 months in patient treated per protocol (P = .45). EST,
Electrical stimulation therapy.
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response.17
PPIs are effective only in the control of
heartburn, not regurgitation. In a meta-analysis,
Kahrilas et al18 reported an average therapeutic
gain with PPI therapy for regurgitation of only
17% compared with placebo. Comparable gains
for heartburn were >20% greater, highlighting
regurgitation as an important factor in PPI fail-
ure.19 Although almost 40% of patients continue
to report bothersome GERD symptoms despite
maximal medical therapy with PPI, <1% will
undergo traditional antireflux surgery.20
Antireflux procedures are recommended for
patients who are unsatisfied with medical therapy.
Estimations put that number for patients in the
United States unsatisfied with medical therapy to
be as great as 10 million. However, at its peak in
2000, 32,980 antireflux operations were per-
formed, and these numbers decreased to 19,668
procedures in 2006.21 These data suggest a sub-
stantial therapy gap in the management of
GERD. The reasons for lack of more widespread
use of laparoscopic, antireflux surgery despite a
large patient population in need of therapy
include both patient and physician fear of side
effects and postoperative complications.9 In fact,
guidelines reported by the American Gastroentero-
logical Association Institute state that ‘‘from the
vantage point of risk, PPI therapy should bestrongly recommended as initial therapy in view
of its superior safety profile’’ despite superior effi-
cacy of antireflux operations in control of symp-
toms of both heartburn and regurgitation.22
Additionally, long-term failure of antireflux sur-
gery and poorer outcomes from low-volume
compared with high-volume centers remain
dissuading factors.23 Multiple endoscopic and sur-
gical device-based therapies have been attempted
to address the incomplete PPI responder patient
population with mixed results.10,11
The lack of clinically relevant side effects,
coupled with the ease of reversibility and noninva-
sive therapy adjustment, makes EST an attractive
option for treating various diseases, including
GERD. Early animal and human studies of LES
stimulation showed an improvement in LES func-
tion without a negative effect on LES relaxation
and esophageal body function.13,24,25 During a
follow-up of 1 year, LES-EST was found to be safe
and effective for the treatment of GERD.14 There
was a significant and sustained improvement in
GERD symptoms and a decrease in esophageal
acid exposure with elimination of daily PPI usage
without any therapy-related adverse effects.
Improvement in esophageal acid exposure has
been considered the most objective and robust
measure of control of GERD. At their 2-year follow-
up, patients treated with per-protocol stimulation
demonstrated a sustained improvement in acid
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suggests that LES stimulation improves the LES
function in a sustained fashion over at least a long-
term, 2-year duration. Similar results were also
reported with sustained improvement in GERD-
HRQL scores, elimination in need for daily PPI
medications in most patients, and improvement in
GERD symptoms of both heartburn and regurgi-
tation. The most profound effect on symptoms was
reported in regurgitation and nocturnal symp-
toms, both of which have been identified as the
major cause of patient dissatisfaction, despite
maximal medical therapy.
Prevention of progression of GERD is a desir-
able goal of any therapy; whether LES-EST will be
able to achieve that remains to be ascertained in
longer term studies. Among the small subgroup of
patients (n = 4) who underwent a blinded turn off
of the therapy, a slow deterioration in esophageal
acid exposure was observed over 3 months that
had not deteriorated to the baseline level at the
time of the repeat pH test. This observation sug-
gests that improvement in distal esophageal acid
exposure was related to LES stimulation. Addi-
tionally, and although anecdotal (n = 4), chronic
LES stimulation may result in prolonged improve-
ment of LES function that persists beyond the
duration of stimulation. Interestingly, of these 4
patients with temporary turn off of LES stimula-
tion, only 1 patient reported recurrence of
GERD symptoms at their 3-month, post-blinded,
turn-off follow-up. After successful control of
GERD for a prolonged period, a delay in the
return of symptoms after cessation of therapy
has been reported after PPI medications. Another
possible explanation for this observation could be
an improvement in LES function with chronic
LES stimulation, which deteriorates slowly on
cessation of stimulation, and the symptoms would
recur in the due course of time. In all these pa-
tients, the esophageal acid exposure had
decreased, but had not returned to baseline levels
even after 3 months of cessation of therapy. It is
also plausible that LES stimulation could interfere
with the afferent nerve transmission and lead to
loss of perception of heartburn; this possibility
remains to be evaluated. Slow deterioration in
esophageal acid control and improved GERD
symptomatology after cessation of therapy may
suggest that LES stimulation could prevent deteri-
oration of sphincter function over long-term.
A lack of effect on esophageal body function
and LES relaxation is another advantage of LES
stimulation therapy. Our initial experience with
LES stimulation in patients with GERD suggestedthat EST may be a suitable therapeutic modality in
GERD patients with severe esophageal dysmotility
who otherwise would be unsuitable candidates for
traditional antireflux procedures; however, more
experience is needed in this patient population to
validate our hypothesis.
Side effects or adverse events have been the
‘‘Achilles heel’’ of most antireflux therapies,
including the Nissen fundoplication.9 The superior
safety profile and lack of clinically relevant side ef-
fects with LES-EST will be attractive to patients
seeking an alternative therapeutic option to life-
long medications. Most of the adverse events re-
ported with LES stimulation therapy were typical
of similar laparoscopic implant procedures and
resolved within a few weeks postoperatively. Addi-
tionally, no new-onset dysphagia or other gastroin-
testinal side effects related to stimulation were
reported with LES stimulation therapy. Another
important aspect in considering a permanent
implant for any therapy, especially one being used
for a disease-associated primarily with decreased
quality of life, is its compatibility with MRI ma-
chines. A formal approval for use of full-body
MRI exposure with a 3T MRI machine is awaited.
Our study was an open-label, single-center trial
in a small group of patients and hence suffers from
the usual limitations of the open-label design.
Sustained improvement in esophageal acid expo-
sure in this group of patients over a 2-year period,
however, suggests that these results are likely owing
to the LES stimulation effect. Comparable positive
results with LES stimulation in GERD patients are
being reported from a separate, ongoing, multi-
center trial.26 The trial excluded patients with
moderate and large (>3 cm) hiatal hernias, LES
end-expiratory pressures <5 mmHg, and those
with severe (grade D) esophagitis or long segment
Barrett esophagus. These patients tend to have
more severe esophageal motor dysfunction and
are more likely to suffer from medically refractory
GERD. Efficacy of LES-EST in these subgroups
need to be established.
Although LES pressure was enhanced by EST in
both animal and human trials, including the 1-year
manometry results in this cohort of patients that
showed improvement in LES pressures without any
negative effect on LES relaxation as demonstrated
by unchanged LES residual pressures, improved
LES pressure alone is unlikely to be the only
mechanism yielding our results.14 Other important
mechanisms may include an effect on transient
LES relaxations, LES compliance, or the acid
pocket. The effect of LES-EST on these important
causative variables needs to be evaluated.
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label trial suggests that LES-EST is safe and
effective in treatment of GERD and results in
superior symptom control than that reported
with PPI therapy at baseline. A better understand-
ing of the mechanism of action and improvement
in stimulation algorithms may improve further the
outcomes of this therapy. Sham-controlled trials
comparing EST with no-stimulation and compara-
tive effectiveness trials compared with maximal
medical therapy and antireflux surgery may help
to better establish the role of LES stimulation in
the management of GERD.REFERENCES
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